FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952362276> ?p ?o ?g. }

• W2952362276 endingPage "524" @default.
• W2952362276 startingPage "524" @default.
• W2952362276 abstract "Background: Infections are a typical complication of chronic lymphocytic leukemia (CLL). Guidelines for prevention of infections in patients with CLL receiving ibrutinib is lacking, possibly due to a paucity of data in the literature. Aims: To analyze factors associated with severe bacterial, viral and fungal infections in CLL patients receiving ibrutinib. Methods: Data on bacterial, viral and fungal infections in CLL patients, who received ibrutinib during 3,6-year period from May 2015 to December 2018 in a single centre are presented. Infections were graded according to CTCAE criteria, version IV. Cumulative incidences of infections were estimated according to Kaplan-Meier and comparison between groups was performed using Hazard Ratios and CIs obtained from Cox regression models. Results: The study included 240 CLL patients. The median age was 65 years (range 32–91 years), 154 (64%) were male, 117 (48%) had stage C, 65 (27%) had ECOG status ≥ 2. Two hundred four patients (85%) received ibrutinib as monotherapy, 36 (15%) along with monoclonal antibodies to CD20. The median follow-up was 14.8 months (range 1 - 44 months). Most patients (224, 93%) received ibrutinib for relapse with a median number of previous treatment lines of 3 (range 1–12). Neutropenia (defined as <1000 cells/mkl) prior to ibrutinib was found in 20 patients (8%). Steroid hormones were given to 20 patients. A total of 525 infectious episodes were recorded in 183 patients. Of these, 381 (72.5%) episodes were bacterial/mixed infections, 115 (22%) viral and 29 (5.5%) fungal infections. Among bacterial infections 121 (32%) were scored as grade III, 43 (11%) as grade IV and 7 (1,8%) infections were fatal. The overall cumulative incidence of grade III-V bacterial infections during 12 months was 37% (95% CI 31–43%), viral infections - 28% (95% CI 22–34), and fungal infections 8% (95% CI 4–12). There was a significantly (p < .05) higher cumulative incidence of grade III-V bacterial infections in patients with ≥3 lines of prior therapy (HR: 2.0; 95% CI 1.36–2.97), Binet stage C (HR: 1.4; 95% CI 0.95–2.08), ECOG ≥ 2 (HR: 2.4; 95% CI 1.6–3.6), baseline neutropenia (HR: 1.25; 95% CI 0.73–2.13), as well as in males (HR: 1.8; 95% CI 1.16–2.8, p = 0.004). In a multivariate analysis male gender (RR 1.89, 95% CI 0.5–3, p = 0.006), ECOG ≥ 2 (RR = 1.97, 95% CI 0.5–3) and initial neutropenia (RR = 1.76, 95% CI 0.99–3.1) were significant and independent risk factors. Cumulative incidence of any fungal infections was associated with simultaneous use of corticosteroids (HR: 6; 95% CI 5.85–14,7) and baseline neutropenia (HR: 2.36; 95% CI 0.95–5.85). The only parameter significantly associated with viral infections was ≥3 lines of prior therapy (HR: 1.74; 95% CI 1.06–2.86). As 160 (87%) patients experienced >1 episode of infections, we compared rates of infections expressed as number per 100 patient-months. Grade III-V bacterial infections were significantly associated with ≥3 lines of previous therapy (3,6 vs 2,3), ECOG ≥ 2 (5,72 vs 2,27), male gender (3,2 vs 2,03) and stage C (3,8 vs 2,24). Fungal infections were more frequently observed in patients with a history of >3 lines of treatment (0,87 vs 0,31), initial neutropenia (1,75 vs 0,47), simultaneous use of steroids (1,96 vs 0,39). Summary/Conclusion: Patients with ECOG status >2 and initial neutropenia are at highest risk of severe bacterial infections and may benefit from antibacterial prophylaxis. Antifungal prophylaxis can be considered in patients who receive corticosteroid hormones simultaneously with ibrutinib" @default.
• W2952362276 created "2019-06-27" @default.
• W2952362276 creator A5003766253 @default.
• W2952362276 creator A5007981545 @default.
• W2952362276 creator A5016718397 @default.
• W2952362276 creator A5030912179 @default.
• W2952362276 creator A5042048934 @default.
• W2952362276 creator A5051556295 @default.
• W2952362276 creator A5055147547 @default.
• W2952362276 creator A5061738009 @default.
• W2952362276 creator A5065032302 @default.
• W2952362276 creator A5069318162 @default.
• W2952362276 creator A5073861459 @default.
• W2952362276 creator A5080241817 @default.
• W2952362276 date "2019-06-01" @default.
• W2952362276 modified "2023-09-26" @default.
• W2952362276 title "PS1155 A PHASE I/II STUDY OF THE SYK INHIBITOR ENTOSPLETINIB IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)" @default.
• W2952362276 doi "https://doi.org/10.1097/01.hs9.0000562904.73237.a4" @default.
• W2952362276 hasPublicationYear "2019" @default.
• W2952362276 type Work @default.
• W2952362276 sameAs 2952362276 @default.
• W2952362276 citedByCount "2" @default.
• W2952362276 countsByYear W29523622762020 @default.
• W2952362276 countsByYear W29523622762023 @default.
• W2952362276 crossrefType "journal-article" @default.
• W2952362276 hasAuthorship W2952362276A5003766253 @default.
• W2952362276 hasAuthorship W2952362276A5007981545 @default.
• W2952362276 hasAuthorship W2952362276A5016718397 @default.
• W2952362276 hasAuthorship W2952362276A5030912179 @default.
• W2952362276 hasAuthorship W2952362276A5042048934 @default.
• W2952362276 hasAuthorship W2952362276A5051556295 @default.
• W2952362276 hasAuthorship W2952362276A5055147547 @default.
• W2952362276 hasAuthorship W2952362276A5061738009 @default.
• W2952362276 hasAuthorship W2952362276A5065032302 @default.
• W2952362276 hasAuthorship W2952362276A5069318162 @default.
• W2952362276 hasAuthorship W2952362276A5073861459 @default.
• W2952362276 hasAuthorship W2952362276A5080241817 @default.
• W2952362276 hasBestOaLocation W29523622761 @default.
• W2952362276 hasConcept C126322002 @default.
• W2952362276 hasConcept C203014093 @default.
• W2952362276 hasConcept C207103383 @default.
• W2952362276 hasConcept C2776694085 @default.
• W2952362276 hasConcept C2777063308 @default.
• W2952362276 hasConcept C2777607594 @default.
• W2952362276 hasConcept C2777938653 @default.
• W2952362276 hasConcept C2778461978 @default.
• W2952362276 hasConcept C2778714382 @default.
• W2952362276 hasConcept C2779338263 @default.
• W2952362276 hasConcept C2779878957 @default.
• W2952362276 hasConcept C2780653079 @default.
• W2952362276 hasConcept C44249647 @default.
• W2952362276 hasConcept C71924100 @default.
• W2952362276 hasConceptScore W2952362276C126322002 @default.
• W2952362276 hasConceptScore W2952362276C203014093 @default.
• W2952362276 hasConceptScore W2952362276C207103383 @default.
• W2952362276 hasConceptScore W2952362276C2776694085 @default.
• W2952362276 hasConceptScore W2952362276C2777063308 @default.
• W2952362276 hasConceptScore W2952362276C2777607594 @default.
• W2952362276 hasConceptScore W2952362276C2777938653 @default.
• W2952362276 hasConceptScore W2952362276C2778461978 @default.
• W2952362276 hasConceptScore W2952362276C2778714382 @default.
• W2952362276 hasConceptScore W2952362276C2779338263 @default.
• W2952362276 hasConceptScore W2952362276C2779878957 @default.
• W2952362276 hasConceptScore W2952362276C2780653079 @default.
• W2952362276 hasConceptScore W2952362276C44249647 @default.
• W2952362276 hasConceptScore W2952362276C71924100 @default.
• W2952362276 hasIssue "S1" @default.
• W2952362276 hasLocation W29523622761 @default.
• W2952362276 hasLocation W29523622762 @default.
• W2952362276 hasOpenAccess W2952362276 @default.
• W2952362276 hasPrimaryLocation W29523622761 @default.
• W2952362276 hasRelatedWork W1961905065 @default.
• W2952362276 hasRelatedWork W2026225959 @default.
• W2952362276 hasRelatedWork W2166334906 @default.
• W2952362276 hasRelatedWork W2173371792 @default.
• W2952362276 hasRelatedWork W2287239764 @default.
• W2952362276 hasRelatedWork W2362622618 @default.
• W2952362276 hasRelatedWork W2564505704 @default.
• W2952362276 hasRelatedWork W2606155555 @default.
• W2952362276 hasRelatedWork W2766509541 @default.
• W2952362276 hasRelatedWork W3135053645 @default.
• W2952362276 hasVolume "3" @default.
• W2952362276 isParatext "false" @default.
• W2952362276 isRetracted "false" @default.
• W2952362276 magId "2952362276" @default.
• W2952362276 workType "article" @default.